AI Summary & Key Takeaways
AI InsightFurther research is needed to identify relapse predictors.
📌 3 Key Takeaways
Abstract
Objective: Chorea is a rare hyperkinetic movement disorder in children, characterized by involuntary, irregular, and rapid movements. Sydenham’s chorea (SC), an autoimmune complication of rheumatic fever, is the most common cause of chorea in pediatric populations. This study aims to retrospectively evaluate the clinical features, neuroimaging findings, treatment responses, and prognostic factors in children with choreiform movement disorders, with a focus on relapse rates and treatment efficacy. Materials and Methods: We conducted a retrospective review of pediatric patients diagnosed with choreiform movement disorders at Dr. Sami Ulus Children's Hospital between 2010 and 2018. Demographic data, clinical presentation, neuroimaging findings, treatments, and relapse outcomes were analyzed. Results: Of the 74 patients, 94.6% had secondary chorea, with 91.9% diagnosed with SC. The mean age at diagnosis was 133.5 ± 33.9 months, with 71.2% female. Brain magnetic resonance imaging findings were normal in 71.4% of the patients who underwent it. Haloperidol was the most commonly used treatment, with 87.3% of SC patients showing a positive response. Relapse occurred in 11.6% of patients, with no significant differences in symptom duration, treatment duration, or age at diagnosis between those with and without relapse (p > 0.05). The median time to relapse was 21 months. Conclusion: SC is the most common cause of chorea in children, and haloperidol is an effective first-line treatment. However, relapses remain a concern, highlighting the need for long-term follow-up. No significant differences were found in clinical parameters between relapsing and non-relapsing patients. Further research is needed to identify relapse predictors.